TERT and cutaneous mastocytosis: Previous studies investigating CoM genetic abnormalities had variable, and often small, cohort sizes (n = 16–78), and mostly targeted hotspot mutations known to occur in cutaneous melanoma (CM), namely in BRAF, NRAS, KIT, and the TERT promoter described in on average 40%–50%, 15%–25%, 1%–3%, and ~70% of CM cases, respectively (Broekaert et al., 2010; Carr & Mackie, 1994; Curtin, Busam, Pinkel, & Bastian, 2006; Davies et al., 2002; Handolias et al., 2010; Horn et al., 2013; Huang et al., 2013; Moltara et al., 2018; van 't Veer et al., 1989).